2 ms·
Submission statement of sorts: the NYT article for this was submitted twice in the last two days but got no attention; the pharmaceutical industry seems to be a
by nerdponx 8y ago
Submission statement of sorts: the NYT article for this was submitted twice in the last two days but got no attention; the pharmaceutical industry seems to be a topic of interest here (including some non-mainstream views on characters like Martin Shkreli), so I'm interested to see HN's take on this.
- refurb 8y agoIt’s important to note that this case is for generic drugs, not brand name drugs. The expensive drugs that make the news are generally the branded kind. Generic drugs are usually very cheap due to the level of competition. Interestingly, the US has some of the cheapest generic drug prices in the world due to the level of competition. I had read that for some generic companies, they make almost 100% of their profit by wining patent cases. Once competition ramps up, their margin is razor thin. So based on that, I guess it’s not that surprising companies would collide in order to improve margins.
- bad-joke 8y agoIt's surprising in light of the prevailing idea that markets enforce competition towards the lowest price. This idea forms the basis of the claim that market-driven healthcare benefits consumers by lowering costs.
- ptah 8y agoit is a very elementary idea that applies to few real life markets. things are more complicated than what your learn in basic economics
- Bartweiss 8y ago> applies to few real life markets It applies to almost all real-life markets. It's so standard that we don't even notice it happening, and focus on the exceptions. There is no level of economics you can reach where "competition drives down prices" stops being taken seriously; Nobel-winning left-wing economists like Stiglitz and Krugman accept that as true and relevant. So does Marx(!), who focuses on how lower costs are achieved at the expense of workers rather than capital holders. Restaurants run at effectively zero margin. Lawn chairs and pencils and window blinds sell for essentially the cost of manufacturing and distribution. Even complex services like VOIP calling have moved from high profitable industries to "essentially free". Markets aren't inherently noble any more than they're inherently evil, but a major part of their value is that price-fixing hardly ever works. Without appreciating that, we lose sight of just how strange healthcare (and college, and housing) are. When prices stay far above costs despite what presents itself as competition, there's something significant happening that deserves more attention.
- ptah 8y agoIn almost all markets competition produces pressure towards consolidation and monopolization. You need strong regulation to keep things competitive
- programmertote 8y agoCan you please share where you read that "the US has some of the cheapest generic drug prices"? My mom, who lives in a southeast asian country, came to visit me in the US last month and I asked her to buy generic antibiotics; ear drops; artificial tear drops; generic antihistamines; and they all are much cheaper than what I would have paid here (and are equally effective in a way that I've been weathering fine in this allergy season with these drugs). My significant other, who is from the same country as I, is a medical resident in the US and she still orders meds from her parents.
- tedmiston 8y agoDo you have some example prices for comparison? Most of us have no idea what generic drugs cost outside of the US.
- Bartweiss 8y agoThis is a complicated one: US generics are vastly more expensive than international generics, but at least part of that is because US manufacturers sell those drugs abroad at the cost of production, making up their remaining costs in the US. People in the industry have described it to me as a tactic of "we help people in need, please don't regulate us". This isn't the whole story; east Asian manufacturers also produce cheaper products, for a bunch of reasons from lower costs to lower regulation to lower profits. And it's notably not the case for non-essential, non-basic medicines (e.g. most psychiatric meds), expensive new generics not used abroad, and certain other high-demand generics like insulin. Those are either expensive everywhere, or more expensive in the US than other wealthy countries and largely unused in poorer countries. (How all this relates to your story depends a lot on whether we're talking about Bangladesh or Taiwan.) But as far as generic antibiotics or antihistamines, it's going to be hard to separate "US manufacturers overcharge" from "US manufacturers sell cheap abroad".
- otikik 8y ago> US manufacturers sell those drugs abroad at the cost of production Not everyone agrees with that statement. First of all, purchasing negotiations are all secret. US manufactures could very well be saying one thing, and doing another. Donald Trump said something along those lines some time ago, calling EU "Freeloaders". There is a Wall Street Journal article echoing his comments. Here's an answer from EU's Health Commissioner Vytenis Andriukaitis: https://sciencebusiness.net/news/drug-prices-row-eu-health-chief-hits-back-trump-view-europe-free-loading-us-innovation https://sciencebusiness.net/news/drug-prices-row-eu-health-c... tl;dr: according to him, Trump was just lying.
- Bartweiss 8y agoI appreciate this submission; it's a story that challenges a number of my views, which I think are relatively common around HN. Broadly, I've thought that high drug prices in the US stem from a mix of our bizarre insurance system (which rewards 'ambitious' pricing) and regulation. For name-brand drugs, that's largely patent protections, but even for generics it happens via process patents, high filing-fee barriers to enter markets, and regulatory delays to start production. (See e.g. here: https://slatestarcodex.com/2019/04/30/buspirone-shortage-in-healthcaristan-ssr/ https://slatestarcodex.com/2019/04/30/buspirone-shortage-in-...) I still believe those things are issues. But this story has pushed me to revise how much I think those things matter relative to outright price manipulation. And if the answer is (as I suspect) that clumsy regulation raises costs some everywhere, but gouging raises costs massively for some drugs, then the question of how to fight both problems at once is exceedingly difficult. The only way to escape these sorts of tradeoffs is usually "make better regulations", and it's not clear how we make that happen.
- otikik 8y agoI would say exemplary action would help. Take 4 or 5 of these criminals, strip them of their fortunes, let the press take many pictures of them handcuffed and going to jail, where they will be for 10 years. Also, force the companies to price the drugs accordingly. If we repeat this enough, I'm sure the problem will magically solve itself and suddenly the companies will be able to cope with clumsy regulation just fine.